Novartis to add EBEWE Pharma generic injectables business to Sandoz division

Published: 20-May-2009
Media Pharmaceutical

Novartis is to acquire the generic injectables business of Austrian company EBEWE Pharma for Euro 925m (US$1.2bn), providing its Sandoz generic pharmaceuticals division with an opportunity to grow while improving access to many generic oncology medicines.


Novartis is to acquire the generic injectables business of Austrian company EBEWE Pharma for Euro 925m (US$1.2bn), providing its Sandoz generic pharmaceuticals division with an opportunity to grow while improving access to many generic oncology medicines.

EBEWE Pharma's separate injectable neurological products business is not part of this transaction.

Several of EBEWE Pharma's products - including paclitaxel, epirubicin, methotrexate, oxaliplatin, carboplatin, doxorubicin and gemcitabine - are essential components of standard-of-care guidelines for treating many types of cancers.

Since becoming independent in 2001 through a management buyout, EBEWE Pharma has built a leading position in Europe and in many emerging markets while also establishing a presence in the US. The business has delivered 20% compound annual sales growth since 2006. Net sales in 2008 were €188m (US$272m).

Ready to use liquid formulations, new dosage forms, advanced delivery devices and innovative packaging such as Onco-Safe have been key to this success.

"As the world market for generic injectables to treat cancer continues to expand, our specialist generics business will enjoy a much broader global reach as part of Sandoz," said Friedrich Hillebrand, ceo of EBEWE Pharma.

Sandoz will form a new global centre of excellence around this business, led by Hillebrand and based in Unterach, Austria. Key priorities for this unit include capitalising on EBEWE Pharma's capabilities in hospital marketing and strong customer partnerships, skills in developing differentiated generics and expertise in injectables manufacturing.

Oncology drugs form one of the largest and fastest-growing sectors of the global generic injectables market. Annual sales of the global generic injectables sector were US$10-12bn in 2008, according to IMS Health, with injectable oncology medicines accounting for about 30%. Additionally, injectable oncology medicines with a total of US$9bn of annual sales are expected to lose patent protection by 2015.

  • Companies:
  • Ebewe Pharma
  • Novartis
See more

You may also like

Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

Read more
The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  4. AstraZeneca appoints Iskra Reic as its International Executive Vice President Iskra will be responsible for championing AstraZeneca's growth across key markets globally, as well as business strategy development
  5. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
Pharmaceutical

Pharma giants Roche and Novartis top worldwide reputation poll

The report examined the reputations of the 34 biggest pharmaceutical companies globally, including GSK, Novartis, Pfizer, Moderna and Johnson & Johnson
Manufacturing

Novartis opens facility for innovative cell and gene therapies in Switzerland

New building in Stein also hosts the production of difficult-to-manufacture solid dosage forms
Finance

Lonza to buy sterile drug product fill-finish facility from Novartis

Swiss CDMO bids to keep management and operations teams and manufacture for Novartis at the site in Stein
Regulatory

Novartis starts voluntary recall after peanut contamination scare

Three lots of Promacta 12.5 mg for oral suspension to the consumer level have been recalled due to cross-contamination risk
Research & Development

Blackstone and Novartis: Joint venture targets cardiovascular disease

Anthos Therapeutics enters the market with US$250 million backing from Blackstone and an anti-thrombotic licensed from Novartis
Ingredients

Therapeutics: anticancer agent: alpelisib

Phosphoinositide 3-kinase enzymes are a group of intracellular signal transducers that phosphorylate the 3-hydroxyl group of phosphatidylinositol
Subscribe now